Cidara Therapeutics, Inc.
CDTX
$22.50
$0.140.63%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 277.13% | 86.71% | |||
| Gross Profit | -277.13% | -95.58% | |||
| SG&A Expenses | 47.19% | 4.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 211.50% | 52.54% | |||
| Operating Income | -211.50% | -56.69% | |||
| Income Before Tax | -237.10% | 83.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -237.10% | 83.51% | |||
| Earnings from Discontinued Operations | 113.78% | -115.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -227.23% | 82.47% | |||
| EBIT | -211.50% | -56.69% | |||
| EBITDA | -212.00% | -56.84% | |||
| EPS Basic | -119.66% | 87.75% | |||
| Normalized Basic EPS | -126.29% | -16.41% | |||
| EPS Diluted | -119.58% | 87.75% | |||
| Normalized Diluted EPS | -126.29% | -16.41% | |||
| Average Basic Shares Outstanding | 48.97% | 43.08% | |||
| Average Diluted Shares Outstanding | 48.97% | 43.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
